This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Excoffon, K. J. D. A. Articles by Lewis, M. E. S. Search for Related Content PubMed PubMed Citation Articles by Excoffon, K. J. D. A. Articles by Lewis, M. E. S.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2532-2539.)
© 1997 American Heart Association, Inc.

Articles

Correction of Hypertriglyceridemia and Impaired Fat Tolerance in Lipoprotein Lipase–Deficient Mice by Adenovirus-Mediated Expression of Human Lipoprotein Lipase

Katherine J. D. Ashbourne Excoffon; Guoqing Liu; Li Miao; Janet E. Wilson; Bruce M. McManus; Clay F. Semenkovich; Trey Coleman; Patrick Benoit; Nicolas Duverger; Didier Branellec; Patrice Denefle; Michael R. Hayden; ; M. E. Suzanne Lewis

From the Departments of Medical Genetics (K.J.D.A.E., G.L., L.M., M.R.H, M.E.S.L.) and Pathology (J.E.W., B.M.M.), University of British Columbia, Vancouver, Canada; Department of Medicine, Washington University, St Louis, Mo (C.F.S., T.C.); and Gencell/Rhone-Poulenc Rorer, Vitry Sur Seine, France (P.B., N.D., D.B., P.D.).

Abstract Humans homozygous or heterozygous for mutations in the lipoprotein lipase (LPL) gene demonstrate significant disturbances in plasma lipoproteins, including raised triglyceride (TG) and reduced HDL cholesterol levels. In this study we explored the feasibility of adenovirus-mediated gene replacement therapy for LPL deficiency. A total of 5x10⁹ plaque-forming units (pfu) of an E1/E3–deleted adenovirus expressing either human LPL (Ad-LPL) or the bacterial ß-galactosidase gene (Ad-LacZ) as a control were administered to mice heterozygous for targeted disruption in the LPL gene (n=57). Peak expression of total postheparin plasma LPL activity was observed at day 7 in Ad-LPL mice versus Ad-LacZ controls (834±133 vs 313±89 mU/mL, P<.01), and correlated with human-specific LPL activity (522±219 mU/mL) and mass (9214±782 ng/mL), a change that was significant to 14 and 42 days, respectively. At day 7, plasma TGs were significantly reduced relative to Ad-LacZ mice (0.17±0.07 vs 1.90±0.89 mmol/L, P<.01) but returned to endogenous levels by day 42. Ectopic liver expression of human LPL was confirmed by in situ hybridization analysis and from raised LPL activity and mass in liver homogenates. Analysis of plasma lipoprotein composition revealed a marked decrease in VLDL-derived TGs. Severely impaired oral and intravenous fat-load tolerance in LPL-deficient mice was subsequently corrected after Ad-LPL administration and closely paralleled that observed in wild-type mice. These findings suggest that liver-targeted, adenovirus-mediated LPL gene transfer offers an effective means for transient correction of altered lipoprotein metabolism and impaired fat tolerance due to LPL deficiency.

Key Words: gene therapy • chylomicronemia • adenovirus • lipolysis • animal models

This article has been cited by other articles:

				M. Gustafsson, M. Levin, K. Skalen, J. Perman, V. Friden, P. Jirholt, S.-O. Olofsson, S. Fazio, M. F. Linton, C. F. Semenkovich, et al. Retention of Low-Density Lipoprotein in Atherosclerotic Lesions of the Mouse: Evidence for a Role of Lipoprotein Lipase Circ. Res., October 12, 2007; 101(8): 777 - 783. [Abstract] [Full Text] [PDF]

				R. A. Hegele, C. J.D. Ross, J. Twisk, J. A. Kuivenhoven, J. Rip, J. J. Kastelein, and M. R. Hayden Gene therapy with lipoprotein lipase variant S447X. Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): e25 - e25. [Full Text] [PDF]

				T. Pulinilkunnil and B. Rodrigues Cardiac lipoprotein lipase: Metabolic basis for diabetic heart disease Cardiovasc Res, February 1, 2006; 69(2): 329 - 340. [Abstract] [Full Text] [PDF]

				J. F. P. Berbee, C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. N. Rensen Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL J. Lipid Res., February 1, 2005; 46(2): 297 - 306. [Abstract] [Full Text] [PDF]

				T. Koike, J. Liang, X. Wang, T. Ichikawa, M. Shiomi, G. Liu, H. Sun, S. Kitajima, M. Morimoto, T. Watanabe, et al. Overexpression of Lipoprotein Lipase in Transgenic Watanabe Heritable Hyperlipidemic Rabbits Improves Hyperlipidemia and Obesity J. Biol. Chem., February 27, 2004; 279(9): 7521 - 7529. [Abstract] [Full Text] [PDF]

				B. S. Zuckerbraun and E. Tzeng Vascular Gene Therapy: A Reality of the 21st Century Arch Surg, July 1, 2002; 137(7): 854 - 861. [Abstract] [Full Text] [PDF]

				S. M. Clee, N. Bissada, F. Miao, L. Miao, A. D. Marais, H. E. Henderson, P. Steures, J. McManus, B. McManus, R. C. LeBoeuf, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis J. Lipid Res., April 1, 2000; 41(4): 521 - 531. [Abstract] [Full Text]

				V. P. Knutson The Release of Lipoprotein Lipase from 3T3-L1 Adipocytes Is Regulated by Microvessel Endothelial Cells in an Insulin-Dependent Manner Endocrinology, February 1, 2000; 141(2): 693 - 701. [Abstract] [Full Text] [PDF]

				C. F. Semenkovich, T. Coleman, and A. Daugherty Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice J. Lipid Res., June 1, 1998; 39(6): 1141 - 1151. [Abstract] [Full Text]

				J. G. Strauss, S. Frank, D. Kratky, G. Hammerle, A. Hrzenjak, G. Knipping, A. von Eckardstein, G. M. Kostner, and R. Zechner Adenovirus-mediated Rescue of Lipoprotein Lipase-deficient Mice. LIPOLYSIS OF TRIGLYCERIDE-RICH LIPOPROTEINS IS ESSENTIAL FOR HIGH DENSITY LIPOPROTEIN MATURATION IN MICE J. Biol. Chem., September 21, 2001; 276(39): 36083 - 36090. [Abstract] [Full Text] [PDF]